Walleye Capital LLC Editas Medicine, Inc. Call Options Transaction History

Walleye Capital LLC

  • $46.2 Billion
  • Q3 2024

Call Options

13 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.39 - $5.96 $1,356 - $2,384
-400 Reduced 0.44%
91,400 $311,000
Q2 2024

Aug 14, 2024
BUY
$4.67 - $7.28 $202,211 - $315,224
43,300 Added 89.28%
91,800 $428,000
Q1 2024

May 15, 2024
BUY
$7.03 - $11.07 $340,955 - $536,895
48,500 New
48,500 $359,000
Q2 2023

Aug 14, 2023
SELL
$6.36 - $11.47 $46,428 - $83,731
-7,300 Reduced 32.3%
15,300 $125,000
Q1 2023

May 15, 2023
BUY
$7.03 - $11.53 $14,763 - $24,213
2,100 Added 10.24%
22,600 $163,000
Q4 2022

Feb 14, 2023
BUY
$8.32 - $13.21 $168,896 - $268,163
20,300 Added 10150.0%
20,500 $181,000
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $2,432 - $3,884
200 New
200 $2,000
Q2 2020

Aug 14, 2020
SELL
$18.5 - $34.34 $166,500 - $309,060
-9,000 Closed
0 $0
Q1 2020

May 15, 2020
SELL
$14.88 - $32.78 $74,400 - $163,900
-5,000 Reduced 35.71%
9,000 $178,000
Q4 2019

Feb 14, 2020
SELL
$19.49 - $32.63 $81,858 - $137,046
-4,200 Reduced 23.08%
14,000 $415,000
Q3 2019

Nov 14, 2019
BUY
$22.49 - $26.81 $56,224 - $67,025
2,500 Added 15.92%
18,200 $414,000
Q2 2019

Aug 14, 2019
BUY
$20.48 - $27.76 $286,720 - $388,640
14,000 Added 823.53%
15,700 $388,000
Q1 2019

May 15, 2019
BUY
$19.43 - $26.41 $33,031 - $44,897
1,700 New
1,700 $42,000

Others Institutions Holding EDIT

# of Institutions
247
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email